Prevalence of Vision Loss in North Africa and Middle East in 2020: Magnitude and Temporal Trends.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

Ophthalmic epidemiology Pub Date : 2025-04-02 DOI:10.1080/09286586.2025.2457629

Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators

{"title":"Prevalence of Vision Loss in North Africa and Middle East in 2020: Magnitude and Temporal Trends.","authors":"Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators","doi":"10.1080/09286586.2025.2457629","DOIUrl":null,"url":null,"abstract":"Purpose: The purpose of the current study was to update the prevalence of blindness and visual impairment (VI) in North Africa and the Middle East (NAME) region and to address the current status of its trends in 2020.Methods: We performed a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We assessed the prevalence of blindness, moderate and severe VI (MSVI), severe VI, moderate VI, mild VI, and presbyopia in NAME region in 2020.Results: In NAME region in 2020, the age-standardised prevalence per 1000, for all ages and sexes, was 0.70 (0.59-0.80) for blindness, 4.31 (3.91-4.72) for MSVI, 0.54 (0.47-0.60) for severe VI, 3.77 (3.38-4.18) for moderate VI, 2.68 (2.42-2.97) for mild VI, and 3.21 (2.29-4.35) for presbyopia. The all-ages and ≥50 year's age-standardised prevalence were higher in females than in males for all categories of vision impairment. In 2020, 3.09 (2.51-3.75) million people were blind, 21.83 (18.97-24.97) million had MSVI, 2.53 (2.11-3.03) million had severe VI, and 19.30 (16.57-22.27) million had moderate VI. Between 2000 and 2020, age-standardised prevalence of blindness and other categories of visual impairment decreased in all ages and among adults over than 50 years.Conclusion: Although the absolute numbers of people with blindness and MSVI have increased between 1990 and 2020 in NAME region, the overall prevalence and the age standardized prevalence in those aged 50+ years have decreased significantly for the same period.","PeriodicalId":19607,"journal":{"name":"Ophthalmic epidemiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09286586.2025.2457629","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The purpose of the current study was to update the prevalence of blindness and visual impairment (VI) in North Africa and the Middle East (NAME) region and to address the current status of its trends in 2020.

Methods: We performed a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We assessed the prevalence of blindness, moderate and severe VI (MSVI), severe VI, moderate VI, mild VI, and presbyopia in NAME region in 2020.

Results: In NAME region in 2020, the age-standardised prevalence per 1000, for all ages and sexes, was 0.70 (0.59-0.80) for blindness, 4.31 (3.91-4.72) for MSVI, 0.54 (0.47-0.60) for severe VI, 3.77 (3.38-4.18) for moderate VI, 2.68 (2.42-2.97) for mild VI, and 3.21 (2.29-4.35) for presbyopia. The all-ages and ≥50 year's age-standardised prevalence were higher in females than in males for all categories of vision impairment. In 2020, 3.09 (2.51-3.75) million people were blind, 21.83 (18.97-24.97) million had MSVI, 2.53 (2.11-3.03) million had severe VI, and 19.30 (16.57-22.27) million had moderate VI. Between 2000 and 2020, age-standardised prevalence of blindness and other categories of visual impairment decreased in all ages and among adults over than 50 years.

Conclusion: Although the absolute numbers of people with blindness and MSVI have increased between 1990 and 2020 in NAME region, the overall prevalence and the age standardized prevalence in those aged 50+ years have decreased significantly for the same period.

查看原文本刊更多论文

2020年北非和中东地区视力丧失的患病率：规模和时间趋势。

目的：本研究的目的是更新北非和中东（NAME）地区失明和视力障碍（VI）的流行情况，并解决2020年其趋势的现状。方法：我们对1980年1月至2018年10月以人群为基础的眼病调查进行了系统回顾和荟萃分析。我们评估了2020年NAME地区失明、中重度VI （MSVI）、重度VI、中度VI、轻度VI和老花眼的患病率。结果：2020年，在NAME地区，所有年龄和性别的年龄标准化患病率为：失明0.70(0.59 ~ 0.80)，重度VI为0.54(0.47 ~ 0.60)，中度VI为3.77(3.38 ~ 4.18)，轻度VI为2.68(2.42 ~ 2.97)，老花眼为3.21（2.29 ~ 4.35）。在所有类别的视力损害中，女性的所有年龄和≥50岁的年龄标准化患病率均高于男性。2020年，3009（2551 - 375）万人失明，2183（1897 - 2497）万人重度VI， 2553（211 - 303）万人重度VI， 1930（1657 - 2227）万人中度VI。2000 - 2020年，各年龄段和50岁以上成年人的年龄标准化失明和其他类别视力障碍患病率下降。结论：1990 - 2020年，虽然NAME地区失明和MSVI的绝对人数有所增加，但同期50岁以上人群的总体患病率和年龄标准化患病率明显下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic epidemiology 医学-眼科学

CiteScore

3.70

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Ophthalmic Epidemiology is dedicated to the publication of original research into eye and vision health in the fields of epidemiology, public health and the prevention of blindness. Ophthalmic Epidemiology publishes editorials, original research reports, systematic reviews and meta-analysis articles, brief communications and letters to the editor on all subjects related to ophthalmic epidemiology. A broad range of topics is suitable, such as: evaluating the risk of ocular diseases, general and specific study designs, screening program implementation and evaluation, eye health care access, delivery and outcomes, therapeutic efficacy or effectiveness, disease prognosis and quality of life, cost-benefit analysis, biostatistical theory and risk factor analysis. We are looking to expand our engagement with reports of international interest, including those regarding problems affecting developing countries, although reports from all over the world potentially are suitable. Clinical case reports, small case series (not enough for a cohort analysis) articles and animal research reports are not appropriate for this journal.